Santaris Pharma A/S - Product Pipeline Review - 2013


Naperville, IL -- (SBWIRE) -- 10/08/2013 -- Reportstack, provider of premium market research reports announces the addition of Santaris Pharma A/S - Product Pipeline Review - 2013 market report to its offering
Santaris Pharma A/S - Product Pipeline Review - 2013


Global Market Directs pharmaceuticals report, Santaris Pharma A/S - Product Pipeline Review - 2013 provides data on the Santaris Pharma A/Ss research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Santaris Pharma A/Ss corporate website, SEC filings, investor presentations and featured press releases, both from Santaris Pharma A/S and industry-specific third party sources, put together by team.


- Santaris Pharma A/S - Brief Santaris Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Santaris Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Santaris Pharma A/S with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Santaris Pharma A/Ss pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Santaris Pharma A/Ss strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Santaris Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Santaris Pharma A/Ss R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Santaris Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Santaris Pharma A/S and identify potential opportunities in those areas.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604